Market Intelligence, Isoform Selectivity Challenges, and High-Purity Biochemical Reagents for Class IIb HDAC Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HDAC10 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Enzyme | HDAC10 Recombinant Protein (Full-Length or Catalytic Domain). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW validated by mass spec. | View HDAC10 Products |
| Gene Delivery | HDAC10 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. HEK293 expressed. | View HDAC10 Products |
| Benchmark Control / Antibody | Anti-HDAC10 Control (Research Grade) / Benchmark Inhibitor. Recombinant monoclonal for IP/Western and enzymatic inhibition controls. | View HDAC10 Products |
| Validator | HDAC10 siRNA Set. For knockdown verification and specificity controls. Validated >80% knockdown. | View HDAC10 Products |
| Related Target - HDAC6 | Class IIb homology - Critical for selectivity profiling. Tubulin deacetylase. | View HDAC6 Products |
| Related Target - RAD51 | Downstream DNA repair pathway marker. Homologous recombination. | View RAD51 Products |
| Related Target - HDAC1 | Class I counter-screen - Safety/toxicity assessment. | View HDAC1 Products |
| Related Target - ACSS2 | Metabolic pathway synergy - Autophagy axis. Acetyl-CoA synthetase. | View ACSS2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (vs HDAC6 and Class I/IIa/IIb) | Purity-verified (>95%) HDAC1/2/3/6/8 panel proteins for orthogonal cross-screening. Mass spec and enzymatic assay verified. |
| Catalytic Domain Conformation | Sequence-verified active domain constructs; Theoretical MW confirmed by mass spec. Mammalian/HEK293 expression ensures native folding and post-translational modifications. |
| Cellular Target Engagement | Validated siRNA included for loss-of-function correlation. Lentiviral particles for overexpression studies. |
| Off-target Safety Profiling | Class I HDAC protein panel (HDAC1/2/3) and HDAC6 for selectivity index determination. Clinical benchmark tools included. |
| Lack of Rigorous Controls | Clinical Benchmark tools and validated siRNA included for specificity checks, reducing false positives. |
Live HDAC10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for HDAC10 is shifting rapidly from pan-HDAC inhibition toward highly selective Class IIb targeting. Unlike Class I HDACs (1, 2, 3) which are essential for cell viability and associated with dose-limiting toxicities (cardiac toxicity, myelosuppression), HDAC10 offers a unique safety profile linked to autophagy regulation and immune cell modulation rather than global transcriptional repression. As first-generation therapies reach the clinic, the next wave of R&D targets selective polyamine deacetylase inhibition to disrupt autophagy in therapy-resistant solid tumors, particularly neuroblastoma. Current R&D trends emphasize isoform-selective small molecules capable of distinguishing HDAC10 from HDAC6 and Class I enzymes, exploiting structural differences in the catalytic channel and cap group binding regions. Major players are advancing compounds into preclinical safety profiling for oncology and autoimmune indications, with growing interest in PROTAC degraders, covalent inhibitors, and allosteric modulators.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule | Early-stage biotech, Tubulis, Mirati, Constellation | Neuroblastoma, Solid Tumors, AML | Isoform Selectivity Panel (Need HDAC1/2/3/6/8 proteins) |
| Covalent Inhibitor | Acetylon (Celgene), Regenacy | Peripheral Neuropathy | Active Site Accessibility Assay (Need native conformation proteins) |
| PROTAC Degrader | Arvinas, C4 Therapeutics | CRPC, Immuno-oncology | Binary/Ternary Complex Formation (Need high-purity HDAC10 antigen) |
| Allosteric Modulator | Academic Consortia | Neurodegeneration | Conformational Selectivity (Need full-length vs catalytic domain) |
| Combination Therapy | Oncology Consortia | Chemo-resistant tumors | Biomarker Validation (Need stable lentiviral cell lines) |
Key Assay Strategies for HDAC10 Drug Discovery
- Isoform Selectivity Profiling: Use purified HDAC1, 2, 3, 6, 8 panel for orthogonal counter-screening. A >100-fold selectivity over Class I and >50-fold over HDAC6 is recommended to avoid toxicity.
- Binding Kinetics Assessment: Leverage SPR/BLI with full-length and catalytic domain proteins to determine residence time (slow off-rate preferred for sustained autophagy disruption).
- Functional Autophagy Assay: Combine siRNA knockdown with LC3-II accumulation readout to confirm target engagement in cells. Use lentiviral overexpression lines for mechanistic studies.
- Resistance Mutation Pre-screening: Prepare mutant proteins (e.g., Y304F, G305A based on homology models) for secondary screening to anticipate acquired resistance.